

Paula L Mcclean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577497/publications.pdf>

Version: 2024-02-01

33
papers

3,193
citations

331259

21
h-index

414034

32
g-index

42
all docs

42
docs citations

42
times ranked

3985
citing authors

#	ARTICLE	IF	CITATIONS
1	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. <i>Journal of Clinical Investigation</i> , 2012, 122, 1339-1353.	3.9	697
2	The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 6587-6594.	1.7	559
3	Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014, 76, 57-67.	2.0	267
4	GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1746-E1755.	1.8	211
5	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010, 630, 158-162.	1.7	163
6	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2012, 33, 265-276.	1.5	144
7	The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid- β Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 102-114.	1.8	134
8	Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014, 86, 241-258.	2.0	130
9	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. <i>Neurobiology of Aging</i> , 2016, 38, 151-163.	1.5	102
10	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. <i>Metabolites</i> , 2017, 7, 28.	1.3	102
11	Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. <i>Behavioural Brain Research</i> , 2015, 293, 96-106.	1.2	94
12	A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APP ^{swe} /PS1 ^{E9} Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e54769.	1.1	76
13	A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. <i>Expert Systems With Applications</i> , 2019, 130, 157-171.	4.4	73
14	Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. <i>Neural Regeneration Research</i> , 2018, 13, 1719.	1.6	59
15	Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 423-434.	2.0	56
16	Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1166-1175.	2.2	49
17	Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide. <i>Microcirculation</i> , 2015, 22, 133-145.	1.0	40
18	Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. <i>Biological Chemistry</i> , 2009, 390, 75-80.	1.2	34

#	ARTICLE	IF	CITATIONS
19	Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 572-579.	1.7	29
20	Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: A longitudinal retrospective study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12122.	1.8	28
21	Shaping a data-driven era in dementia care pathway through computational neurology approaches. <i>BMC Medicine</i> , 2020, 18, 398.	2.3	24
22	Early Stage Glycosylation Biomarkers in Alzheimer's Disease. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 92.	0.7	22
23	Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. <i>Journal of Peptide Science</i> , 2007, 13, 400-405.	0.8	20
24	Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 818-827.	3.9	18
25	Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease. <i>Neuropharmacology</i> , 2020, 174, 108118.	2.0	14
26	Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. <i>Experimental Gerontology</i> , 2007, 42, 296-300.	1.2	10
27	An Early Stage Researcher's Primer on Systems Medicine Terminology. <i>Network and Systems Medicine</i> , 2021, 4, 2-50.	2.7	9
28	Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy and Administration Time. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2022, 10, 1-9.	2.2	6
29	Effects of Subchronic Treatment With the Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist, N-AcGIP, on Glucose Homeostasis in Streptozotocin-Induced Diabetes. <i>Pancreas</i> , 2007, 35, 73-79.	0.5	5
30	Multi-timepoint data preparation robustly reveals MCI and dementia risk factors. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12116.	1.2	4
31	Computational Neurology: Computational Modeling Approaches in Dementia. , 2021, , 81-89.		2
32	Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, , e00326.	1.0	1
33	Alterations of plasma endocannabinoid levels in MCI and dementia patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0